Fuller & Thaler Asset Management
ALXN

Fuller & Thaler Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Fuller & Thaler Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,400
Closed -$243K – 751
2015
Q1 		$243K Sell
1,400
-1,200
-46% -$217K 0.01% 384
2014
Q4 		$481K Buy
2,600
+400
+18% +$74.1K 0.02% 320
2014
Q3 		$365K Sell
2,200
-200
-8% -$32.8K 0.02% 360
2014
Q2 		$375K Sell
2,400
-3,100
-56% -$489K 0.02% 354
2014
Q1 		$837K Buy
5,500
+4,200
+323% +$668K 0.04% 276
2013
Q4 		$173K Buy
1,300
+500
+63% +$60K 0.01% 424
2013
Q3 		$93K Buy
+800
New +$87.8K 0.01% 519

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Fuller & Thaler Asset Management's ALXN Position: Q2 2015 in Review

Fuller & Thaler Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2015, closing a stake of 1,400 shares — an estimated $243K sold.

Fuller & Thaler Asset Management first reported a position in ALXN in Q3 2013 and held it in 7 quarters. The position peaked at $837K in Q1 2014. 548 funds tracked by Wall St. Rank hold ALXN as of Q2 2015.

  • Fuller & Thaler Asset Management reported no remaining Alexion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Fuller & Thaler Asset Management sold 1,400 Alexion Pharmaceuticals shares in Q2 2015, an estimated $243K.
  • Fuller & Thaler Asset Management first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 7 quarters.
  • Fuller & Thaler Asset Management's Alexion Pharmaceuticals position peaked at $837K in Q1 2014.
  • 548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2015.

Based on Fuller & Thaler Asset Management's 13F filing for Q2 2015, filed 17 Aug 2015.